Molecular Imaging

Ratio Therapeutics signs Ac-225 supply agreement with PanTera

By AuntMinnie.com staff writers

Deal will support Ratio's alpha therapy programs.

June 30, 2026

Business Deal Corporate 400

Novel SST2-PET tracer shows promise in patients with NETs

With a half-life of 3.3 hours, cyclotron-produced Cu-61 NODAGA-LM3 could allow delayed imaging and centralized distribution.

June 25, 2026

Maximum intensity projections showing biodistribution of Cu-61 NODAGA-LM3 (146 MBq) in a patient with a metastatic non-functional NET of the pancreas G2 (Ki-67: 5%) with lymph node, hepatic, osseous, and peritoneal as well as ovarian metastases. PET performed a 1-hour, 3-hours, and 18-hours post-injection show high and prolonged tumor uptake and excellent image contrast, with low uptake in the liver, intestinal tract, and other non-target organs.

PET RANO gains visibility as neurotheranostics research advances

By Claudia Tschabuschnig

Standardized PET response assessment, emerging theranostic targets, and new strategies to overcome the blood-brain barrier are among the developments shaping neuro-oncology research.

June 24, 2026

As theranostics advances, access challenges remain across Europe

By Claudia Tschabuschnig

Theranostics is advancing rapidly, but access remains uneven across Europe. According to Prof. Clemens Decristoforo, differences in national regulations and healthcare systems continue to influence patient access to innovative radiopharmaceuticals.

June 24, 2026

Prof. Clemens Decristoforo is a member of the EANM Policy & Regulatory Affairs Council and professor at the Department of Nuclear Medicine at the Medical University of Innsbruck.

Six European societies launch RLT Referral Pathways Project

By Claudia Tschabuschnig

Radioligand therapy has proven itself clinically for advanced prostate cancer. What hasn't caught up is Europe's healthcare infrastructure.

June 23, 2026

Radiology and nuclear medicine are converging on clinical audit and quality frameworks across Europe.

$9M grant invests in 'next generation' of CAA scientists

By AuntMinnie.com staff writers

Project will combine advanced brain imaging with new molecular biomarkers and innovative experimental models.

June 19, 2026

PET/CT could improve margin assessment for breast tumors

By Amerigo Allegretto

Specimen PET/CT imaging outperforms routine intraoperative margin assessment in breast tumors.

June 19, 2026

Pet Scan Patient 400 (1)

Siemens Healthineers announces U.K. radiopharmacy expansion in Dunstable

By AuntMinnieEurope.com staff writers

Investment supports increased output and same-day delivery of PET radiopharmaceuticals and theranostics agents.

June 16, 2026

Dunstable Exterior Final Enhanced Upscaled 4x

Early FAPI-PET scans match 60-minute scans for lung cancer staging

By convention, most molecular imaging tracers such as F-18 FDG are injected one hour prior to PET scans to allow time for uptake of the tracer by tumors.

June 10, 2026

PET/CT images performed at 10- and 60-minutes following injection of Ga-68 FAPI-46 (mean 181 MBq; range 143–225 MBq).

Curium to invest €32M in French radiopharmaceutical facility

By AuntMinnieEurope.com staff writers

The investment will go toward development of a new production line for lutetium-177 PSMA-I&T, a targeted radioligand therapy.

June 1, 2026

France Flag Button 400

SNMMI: SPECT/CT tracer shows promise in interstitial lung disease

Differentiating between fibrotic scarring and inflammation stages of disease is critical so that physicians can determine what treatment is best for the patient.

May 31, 2026

Sample images from each participant group: A: CT only; B: fused Tc-99m maraciclatide SPECT/CT.

SNMMI: Machine-learning model predicts RPT dose

Dosimetry plays a central role in optimizing lutetium-177 (Lu-177) PSMA therapy, yet calculating it currently depends on post-therapy imaging.

May 30, 2026

Page 1 of 127